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Abstract
Background: Data from a randomized multinational phase 3 trial of 320 adults with acute myeloid leukemia (AML)
demonstrated that maintenance therapy with 3-week cycles of histamine dihydrochloride plus low-dose
interleukin-2 (HDC/IL-2) for up to 18 months significantly improved leukemia-free survival (LFS) but lacked power to
detect an overall survival (OS) difference.
Purpose: To assess the consistency of treatment benefit across patient subsets and the robustness of data with
respect to trial centers and endpoints.
Methods: Forest plots were constructed with hazard ratios (HRs) of HDC/IL-2 treatment effects versus no treatment
(control) for prospectively defined patient subsets. Inconsistency coefficients (I
2) and interaction tests (X
2) were
used to detect any differences in benefit among subsets. Robustness of results to the elimination of individual
study centers was performed using “leave-one-center-out” analyses. Associations between treatment effects on the
endpoints were evaluated using weighted linear regression between HRs for LFS and OS estimated within
countries.
Results: The benefit of HDC/IL-2 over controls was statistically consistent across all subsets defined by baseline
prognostic variables. I
2 and P-values of X
2 ranged from 0.00 to 0.51 and 0.14 to 0.91, respectively. Treatment effects
were statistically significant in 14 of 28 subsets analyzed. The “leave-one-center-out” analysis confirmed that no
single center dominated (P-values ranged from 0.004 to 0.020 [mean 0.009]). The HRs representing the HDC/IL-2
effects on LFS and OS were strongly correlated at the country level (R
2 = 0.84).
Limitations: Small sample sizes in some of the subsets analyzed.
Conclusions: These analyses confirm the consistency and robustness of the HDC/IL-2 effect as compared with no
treatment. LFS may be an acceptable surrogate for OS in future AML trials. Analyses of consistency and robustness
may aid interpretation of data from multicenter trials, especially in populations with rare diseases, when the size of
randomized clinical trials is limited.
Trial Registration: ClinicalTrials.gov: NCT00003991
Introduction
The results of a clinical trial should not be assessed
solely in terms of statistical significance. In their Statisti-
cal Principles for Clinical Trials (ICH E9), the Interna-
tional Conference on Harmonization recommends
evaluating “the robustness of the results and primary
conclusions of the trial. Robustness is a concept that
refers to the sensitivity of the overall conclusions to var-
ious limitations of the data, assumptions, and analytic
approaches to data analysis” [1]. Hence a trial that
reached the standard criterion of significance (P <0 . 0 5 )
could still be questioned if its results lacked robustness.
In contrast, when studying diseases of low incidence,
achieving P < 0.05 may require sample sizes that are too
large to be achievable in a reasonable timeframe. Estey
argues that if a disease is relatively uncommon and
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any medium, provided the original work is properly cited.active therapies are lacking, protection against false posi-
tive results with >95% confidence may be too stringent
[2]. This point is clearly illustrated by acute myeloid leu-
kemia (AML), a disease with incidence ranging from 2
to 4 per 100,000 persons in Europe and the United
States [3]. Trials that aim to demonstrate statistically
significant benefits on overall survival (OS) in AML are
especially challenging since they require large numbers
of patients and long durations of follow-up. With typical
costs and time to conduct oncology trials in excess
of $500 million and 10 years, respectively [4], new
approaches to study design and interpretation that help
reduce these burdens are obviously necessary. Inten-
sive efforts are therefore underway to evaluate other
approaches to bring promising new drugs that fulfill
urgent medical needs to patients more efficiently [4-9].
First and foremost, when evaluating new cancer treat-
m e n t s ,an u m b e ro fe f f i c a c ye ndpoints are usually con-
sidered. In both early and advanced disease, commonly
used endpoints are OS and disease or progression-free
survival (DFS or PFS) [6-8]. In the case of acute leuke-
mia, if a trial reaches statistical significance on DFS
(more commonly called leukemia-free survival, LFS) but
not on OS, is it because the treatment actually has an
effect on one endpoint but not on the other, or merely
because the effect seen on LFS is attenuated in the ana-
lysis of OS? In fact, attenuation of the treatment effect
on OS is expected because of three independent factors:
(a) the time lag between leukemia recurrence and death,
which results in a lower hazard ratio for OS than for
LFS for the same absolute number of events; (b) varia-
tions in post-relapse therapies that may have effects on
OS completely unrelated to the treatment being evalu-
ated [10], and (c) competing risks of death that may be
substantial in a disease such a AML, for which the med-
ian age at diagnosis is approaching 70 years [11,12].
Hence in AML, both LFS and OS are important, the
former because it is statistically sensitive to real treat-
ment effects, and the latter because it is the ultimate
endpoint that cancer treatment should affect. Therefore,
an investigation of the relationship between LFS and OS
can be informative, in addition to analyses of each end-
point considered separately.
Second, if an overall treatment effect of a novel ther-
apy is detected, it is of interest to understand whether
the benefit applies to all patients, or if the benefit is
confined to particular patient subsets. This is especially
relevant in a heterogeneous disease such as AML, which
is comprised of small groups of patients with distinctly
different prognoses determined by age, karyotype, cyto-
genetics, and level of minimal residual disease, among
others [2,5]. Such prognostic information is already
being used to direct therapeutic decision-making, and
this trend will undoubtedly increase as more cytogenetic
information about AML becomes available [2]. In this
respect, a study of the consistency of the treatment
effects across subsets of patients based on prognostic
variables can provide useful information to clinicians.
Third, if an overall treatment effect is detected in a mul-
ticenter trial, what assurance can be made that the effect is
not heavily influenced by a single center or very few cen-
ters? In a multinational trial, are the efficacy outcomes and
the treatment effects on these outcomes broadly compar-
able between countries? A study of the robustness of the
treatment effects with respect to centers, and of the con-
sistency of these effects with respect to countries, can pro-
vide assurance that the trial results are broadly
representative and, as such, more likely to be generalizable.
This paper addresses these issues in the context of a
randomized multinational phase 3 trial of histamine dihy-
drochloride, used in conjunction with low-dose interleu-
kin-2 (HDC/IL-2) as remission maintenance therapy in
AML patients [13]. This trial achieved statistical signifi-
cance on LFS (the pre-specified primary endpoint) and
showed that treatment with HDC/IL-2 prolonged LFS
compared to controls (standard-of-care; no treatment).
Although the sample size was substantial for a trial in
AML (320 patients, 236 AML relapses, 196 deaths), the
trial was insufficiently powered to detect an effect on OS
and did not reach statistical significance on the OS end-
point. In this paper, we show that analyses of consistency
and robustness can help interpret these results.
Methods
Phase 3 clinical trial of HDC/IL-2 as maintenance therapy
for AML patients in complete remission
This was a randomized open-label trial of 320 AML
patients in complete remission (CR), post-induction and
consolidation treatment. The trial was conducted accord-
ing to ethical principles stated in the Declaration of Hel-
sinki (October, 1996). The protocol, amendments, and
sample informed consent forms were reviewed and
approved at each of 92 distinct clinical centers by a duly
constituted Institutional Review Board or Independent
Ethics Committee [13]. Each patient was required to read,
understand, sign and date a copy of the informed consent
form in the presence of the investigator (or designee)
before any protocol-specified procedures were undertaken.
A large proportion of patients were in first complete
remission (CR1; n = 261). Patients who received an allo-
geneic transplant during first remission were ineligible.
Immunotherapy with HDC (Ceplene
®, EpiCept Cor-
poration, Tarrytown, NY) was given subcutaneously (sc)
at a dose of 0.5 mg BID in conjunction with IL-2 (Pro-
leukin
®, Chiron, Emeryville, CA [now Novartis]) 16,400
IU/kg sc BID. Following initial supervision and training
to perform sc injections, treatments were self-adminis-
tered by patients for up to 10 × 3-week cycles over a
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received no treatment during this period.
The primary objective of this trial was to determine if
HDC/IL-2 could prolong LFS compared with no treat-
ment. LFS was defined as the number of days from the
date of randomization to the date of relapse of AML or
death from any cause, whichever came first. Relapse was
determined by examination of the bone marrow using
an identical schedule of clinical and laboratory assess-
ments in both treatment arms. The effect of HDC/IL-2
on OS was a secondary endpoint. Hazard ratios (HRs)
for LFS and OS were estimated with a Cox regression
model with treatment as the covariate of interest (coded
1 = treatment, 0 = control, so that HR>1 indicates treat-
ment benefit), and stratification for country and com-
plete remission (CR1 vs CR>1).
In this trial, HDC/IL-2-treated and untreated groups
were well balanced across all demographic and disease
prognostic variables [13]. A significant benefit of HDC/IL-
2 was demonstrated for the primary LFS endpoint (HR =
1.43, P = 0.008), but not for OS (HR = 1.23, P =0 . 1 6 ) .
Treatment with HDC/IL-2 was well-tolerated, with no
treatment-related mortality, significant morbidity, or detri-
mental impact on quality-of-life [14]. Details about the
trial and its major results have been previously reported
[13,14]. Treatment with HDC/IL-2 was approved in
Europe in October 2008 for AML patients in CR1. The
analyses presented herein are by intention-to-treat (ITT)
on all randomized patients. A level of 0.05 was used
throughout as the nominal threshold of statistical signifi-
cance, keeping in mind that P-values of individual tests
must be interpreted with due allowance for multiplicity.
Consistency of treatment effects
Forest plots of LFS HRs were constructed for all prog-
nostic subsets thought to be relevant at the time the
study was conducted. Forest plots were also constructed
for the countries in which patients were treated; the
United Kingdom, Finland, and Estonia had included
only 7 patients in total and were not shown on the
plots.
Tests of heterogeneity (X
2) and inconsistency coeffi-
cients (I
2) were used to assess the observed differences
in LFS HRs among the various subsets [15,16]. The test
statistic for heterogeneity between S subsets, X
2,i s
defined as X
2 = Σ (τi - τ)
2/si
2,w h e r eτi is the treatment
effect in the i
th subset, si is the standard error of τi,a n d
τ is the overall treatment effect. X
2 has a c
2 distribution
with (S - 1) degrees of freedom [15]. The inconsistency
index between S subsets, I
2, is calculated as I
2 =( X
2 -S+
1)/X
2 if X
2 >S-1 ,a n dI
2 =0o t h e r w i s e[ 1 6 ] .I
2 values
indicate little inconsistency if they are under 0.33, moder-
ate inconsistency if they range from 0.33 to 0.67, and
substantial inconsistency if they are above 0.67 [16].
When a subset showed a negative treatment effect (i.e.
patients in the control group fared better than patients in
the treatment group), we calculated the probability that
such a reversal of effect could be observed just by the play
of chance [17]. To calculate an approximate probability,
we observe that if the N patients of the trial are subdivided
in S subsets of equal size, the standard error of the subset-
specific test statistic is equal to √S times the standard
error of the overall test statistic. The probability of a rever-
sal of effect is given by the area under the normal distribu-
tion of the subset-specific test statistic to the left of zero.
Note that for a time to event endpoint such as LFS or OS,
the “size” of a subset is its number of events. Reference
[17] provides further details in the general case.
Robustness of treatment effects
The trial was conducted in 92 distinct clinical centers
with the number of patients treated within these centers
ranging from 1 to 17. The majority of centers had too
few patients to yield informative estimates of treatment
effects. Therefore, a “leave-one-center-out” cross-validation
was performed to assess the robustness of HDC/IL-2
effects with respect to site. P-values for treatment effect
were re-calculated after sequential elimination of indivi-
dual study centers and summarized as a frequency dis-
tribution. In addition, P-values for treatment effect were
re-calculated after successive elimination of the largest
and the smallest centers from the analysis in order to
estimate the number of such eliminations required in
order to lose statistical significance.
Association between treatment effects on different
endpoints
In order to investigate the consistency of outcomes and
of treatment effects, we used the approach developed
for the validation of surrogate endpoints [18,19]. This
approach consists of quantifying the associations
between the two endpoints (LFS, the potential surrogate,
and OS) and between the treatment effects on the two
endpoints [9]. These analyses are described in detail in a
separate manuscript. Here, we focused on the associa-
tion between treatment effects and fitted a weighted lin-
ear regression between the HRs for LFS and OS
estimated within countries. Coefficients of determination
(R
2) were calculated to quantify the proportion of var-
iance explained by the regressions.
Results
Consistency of treatment effects across patient
characteristics and countries
Compared with no treatment, HDC/IL-2 had a statisti-
cally significant benefit on LFS (HR = 1.43, 95% CI =
1.10, 1.87, log-rank test stratified for country and CR
status P = 0.008) [13]. Figure 1 shows forest plots of
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O/N
Treatment
O/N
Adjusted
HR (CI)
Control
better
Treatment
better Strata
Age 60 76/101 56/94 1.64 (1.14,2.37)
Age >60 50/59 54/66 1.21 (0.80,1.82)
Total 126/160 110/160 1.43 (1.09,1.88)
Men 72/86 65/86 1.22 (0.86,1.73)
Women 54/74 45/74 1.84 (1.19,2.85)
Total 126/160 110/160 1.44 (1.09,1.89)
Gender
6 104/126 84/117 1.38 (1.02,1.86)
>6 21/33 26/43 1.44 (0.71,2.94)
Total 125/159 110/160 1.39 (1.05,1.83)
Months from 
current CR to 
randomization
Normal 89/114 83/125 1.43 (1.04,1.96)
Other 37/46 27/35 1.21 (0.67,2.19)
Total 126/160 110/160 1.38 (1.04,1.82)
Baseline
performance
status
100 115/145 101/145 1.50 (1.13,1.98)
>100 8/12 7/12 1.07 (0.18,6.26)
Total 123/157 108/157 1.48 (1.12,1.96)
WBC at
diagnosis 109/L
No 119/149 99/145 1.47 (1.11,1.94)
Yes 7/11 11/15 2.42 (0.43,13.61)
Total 126/160 110/160 1.49 (1.13,1.96)
Karyotype (SWOG)
favorable
0.2
No 71/85 59/84 1.66 (1.13,2.42)
Yes 55/75 51/76 1.22 (0.81,1.84)
Total 126/160 110/160 1.44 (1.09,1.90)
Karyotype (SWOG)
intermediate
No 110/142 95/142 1.50 (1.13,2.00)
Yes 16/18 15/18 1.32 (0.53,3.30)
Total 126/160 110/160 1.48 (1.13,1.95)
Karyotype (SWOG)
unfavorable
AML subtype
(M2/M3/M4)
No 60/67 51/72 1.61 (1.06,2.44)
Yes 66/93 59/88 1.44 (0.98,2.12)
Total 126/160 110/160 1.52 (1.14,2.01)
No 75/104 71/101 1.35 (0.95,1.92)
Yes 51/56 39/59 1.71 (1.06,2.77)
Total 126/160 110/160 1.47 (1.10,1.95)
AML subtype
(M0/M1/M5/M6/M7)
No 113/143 95/138 1.46 (1.09,1.94)
Yes 13/17 15/22 0.89 (0.36,2.21)
Total 126/160 110/160 1.39 (1.06,1.83)
Autologous stem
cell transplant
No 116/149 98/144 1.49 (1.13,1.98)
Yes 9/10 11/15 1.23 (0.41,3.63)
Total 125/159 109/159 1.47 (1.12,1.93)
Extramedullary
leukemia
No 39/48 40/50 1.20 (0.74,1.93)
Yes 84/109 67/107 1.52 (1.08,2.12)
Total 123/157 107/157 1.40 (1.07,1.85)
HiDAC during induction
or consolidation
Age
CR status
CR1 103/132 82/129 1.46 (1.09,1.97)
CR>1 23/28 28/31 1.30 (0.71,2.39)
Total 126/160 110/160 1.43 (1.10,1.87)
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Figure 1 Forest plots of leukemia-free survival (LFS) hazard ratios (HR) and their confidence intervals (CI) by baseline characteristics.
O/N = event rate per arm where O is the number of observed events (relapse or death) and N is the sample size. HR = hazard ratio, CI =
confidence interval, CR = complete remission, CR1 = first complete remission, WBC = white blood cell, SWOG = Southwest Oncology Group,
AML = acute myeloid leukemia, HiDAC = high-dose cytosine arabinoside.
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on baseline patient characteristics: age (> or ≤60 years),
CR status (first [CR1] or subsequent remission [CR >1]),
gender, months from CR to randomization (> or ≤6
months), performance status, white blood cell counts at
diagnosis, Southwest Oncology Group (SWOG) karyo-
type, AML subtype, intensity of prior induction and
consolidation therapy (autologous stem cell transplant
or high dose cytarabine), and presence of extramedullary
leukemia. Adjusted for country and CR status, HRs
reflecting treatment benefit exceeded 1.00 in 27 subsets
out of 28 examined, with statistical significance detected
in 14 of 28 subsets analyzed, indicating consistency
across subsets.
Testing for interactions to determine whether the ben-
efit of HDC/IL-2 differed among these subsets, X
2
values were all non-significant and ranged from X
2
1d.f. =
0.01 to X
2
1d.f. =2 . 0 6 .T h eX
2 for country was also non-
significant, whether the 7 countries with 313 patients
were considered (X
2
6d.f. =9 . 6 3 ,P = 0.14) or whether all
10 countries were included (X
2
9d.f. = 9.86, P = 0.36).
Most I
2 values were either equal to 0 or lower than
0.33, except for gender (I
2 = 0.51) and country (7 coun-
tries, I
2 = 0.38). The moderate inconsistency noted for
gender and country could not be explained either
through confounding factors, or through some other
prior information.
Country-specific HRs stratified by CR-status were lar-
ger than 1.00 in 5 out of 7 countries included in these
analyses (Figure 2), with statistical significance reached
in three of them, indicating that the results were not
driven by a single influential country. The treatment
effect was negative in one country, but with 7 countries
of equal size such a reversal of effect would be expected
to occur just by chance with probability 0.16, which is
close to one in seven.
Robustness of treatment effects
The “leave-one-center-out” cross-validation performed
with the 92 distinct centers yielded P-values ranging
from 0.004 to 0.020 (mean 0.009) for the LFS analysis,
instead of P = 0.008 (for the observed LFS hazard ratio
of 1.43). Hence, the P-value for treatment effect
remained significant after elimination of any study cen-
ter (Figure 3), thereby providing confidence that no
study center was so influential as to drive the statistical
significance of the findings.
When P-values for treatment effect were re-calculated
after successive elimination of several centers from the
analysis, statistical significance was retained until elimi-
nation of the 8 largest centers (HR = 1.32, P = 0.084, 83
patients eliminated), and the 29 smallest centers (HR =
1.32, P = 0.052, 35 patients eliminated).
Association between treatment effects on different
endpoints
Country-specific HRs reflecting the treatment effects on
LFS and OS were highly correlated (Figure 4). The
weighted linear regression equation was HROS =0 . 1 0+
0.86 × HRLFS with a coefficient of determination R
2 =
0.84, indicating that 84% of the variance was explained
by the linear regression (P = 0.004). Hence, the observed
effect of treatment on LFS was a good predictor of the
effect of treatment on OS, with only a slight (14%)
attenuation of the effect as reflected in the slope of 0.86.
Additionally, the fitted regression line passed nearly
through the origin, indicating that no effect on LFS
would predict no or little effect on OS (as expected).
Control
O/N
Treatment
O/N
Adjusted
HR (CI)
Control 
better
Treatment
better Country
USA 34/39 29/39 1.83 (1.09,3.05)
Canada 10/12 9/11 1.33 (0.52,3.38)
France 10/11 8/14 2.97 (1.06,8.28)
Germany 17/21 15/21 1.31 (0.64,2.66)
Sweden 21/30 19/29 1.00 (0.53,1.86)
Australia 20/30 22/32 0.86 (0.47,1.58)
Israel 11/12 6/12 3.66 (1.21,11.05)
ALL 123/155 108/158 1.43 (1.09,1.87)
1.0 0.2 10
Figure 2 Forest plots of leukemia-free survival (LFS) hazard
ratios (HR) and their confidence intervals (CI) by country. O/N
= event rate per arm where O is the number of observed events
(relapse or death) and N is the sample size.
P-Value
N                         
Mean                  
Std deviation    
Minimum           
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Figure 3 Distribution of P-values for the treatment effect on
leukemia-free survival in a “leave-one-center-out” cross-
validation. N = sample size.
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We critically inspected the results of this randomized
phase 3 trial of HDC/IL-2 as remission maintenance
therapy versus no treatment for AML patients in com-
plete remission. Treatment effects were assessed for
consistency and robustness with respect to clinically
relevant prognostic variables and with respect to center
or country where the treatment took place. To this end,
we tested for treatment by subset interactions (Table 1
and Figures 1 and 2), calculated inconsistency indices
(Table 1), performed leave-one-center-out cross-valida-
tion (Figure 3), showed that several centers could be
eliminated before losing statistical significance and cor-
related country-specific treatment effects on LFS and on
OS (Figure 4). Taken together, these analyses indicate
that the benefit of HDC/IL-2 is statistically consistent
and robust.
By “consistent,” we mean that (a) the treatment effects
d on o td i f f e rb ym o r et h a nr a n d o mv a r i a t i o na c r o s s
prognostic factors and other design features such as
country; and (b) the treatment effects on different end-
points are highly correlated. By “robust,” we mean that
(a) the treatment effects would have been about the
same had slightly different patient populations been
included (this aspect of robustness derives directly from
the consistency of the results); and (b) the treatment
effects remain significant even after elimination of a few
centers from the analysis. We suggest that similar
assessments could be useful in all randomized multicen-
ter trials aimed at establishing the efficacy and safety of
new therapies, particularly in trials with limited sample
sizes (eg, resulting from a low incidence of the disease
under study). These analyses would complement other
sensitivity analyses that are recommended to examine
the influence of protocol deviations, unintended biases,
violations of assumptions and other unexpected events
on the trial outcome [1].
It is commonly believed that homogeneity of the
patient population through narrow selection criteria is a
desirable feature of phase 3 clinical trials. This is
because heterogeneity will tend to increase the variance
in patient outcomes, thereby reducing the likelihood of
real treatment effects reaching statistical significance. In
fact, the opposite is true insofar as heterogeneity across
patient and disease characteristics at baseline renders
the results of the trial more generalizable. Moreover, if
patients with widely different baseline characteristics are
included, potential treatment-by-prognostic-factor inter-
actions can be found. To this end, inconsistency indices,
which are commonly used in meta-analyses [16], may
prove more descriptively useful than interaction tests
that generally lack power to detect any but the most
extreme interactions.
Another commonly held view is that having a large
number of sites, as is the case in most cancer trials,
somehow reduces the credibility of the findings. Here
again, the opposite is true. When a trial is able to show
a statistically significant difference despite the presumed
h e t e r o g e n e i t yr e s u l t i n gf r o mt h em u l t i c e n t r i cn a t u r eo f
patient accrual, the trial results are even more convin-
cing, as well as more generalizable, than if all patients
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Figure 4 Correlation between treatment effects on leukemia-
free survival and overall survival (R
2 = coefficient of
determination). The size of each circle is proportional to the
number of patients in the corresponding country.
Table 1 Heterogeneity test statistics (X
2) and
inconsistency coefficients (I
2) for baseline disease
characteristics, corresponding to the hazard ratio forest
plots of Figures 1 and 2
Baseline disease characteristic X
2 (P-value) I
2
Age (≤60 vs >60) 1.19 (0.28) 0.16
CR status (CR1 vs CR >1) 0.12 (0.73) 0.00
Gender (Men vs Women) 2.06 (0.15) 0.51
Months from current CR to randomization (≤6 vs >6) 0.01 (0.91) 0.00
Performance status (Normal vs Other) 0.23 (0.63) 0.00
WBC at diagnosis (10
9/L) (≤100 vs >100) 0.13 (0.71) 0.00
Karyotype (SWOG): Favorable (No vs Yes) 0.31 (0.58) 0.00
Karyotype (SWOG): Intermediate (No vs Yes) 1.16 (0.28) 0.14
Karyotype (SWOG): Unfavorable (No vs Yes) 0.07 (0.79) 0.00
AML subtype: M0/M1/M5/M6/M7 (No vs Yes) 0.60 (0.44) 0.00
AML subtype: M2/M3/M4 (No vs Yes) 0.14 (0.71) 0.00
Autologous stem cell transplant (No vs Yes) 1.03 (0.31) 0.03
Extramedullary leukemia (No vs Yes) 0.12 (0.73) 0.00
High dose of cytarabine received (No vs Yes) 0.63 (0.43) 0.00
Country (7 countries) 9.63 (0.14) 0.38
Country (10 countries) 9.86 (0.36) 0.09
CR = complete remission, CR1 = first complete remission, SWOG = Southwest
Oncology Group.
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ment of the robustness of the trial results may be useful
regardless of the number of centers participating in a
trial, but they are more likely to be convincing if a large
number of centers participated in the trial, as was the
case in the trial analyzed in the present paper.
Although there is little question that the results of this
trial were consistent and robust, the point estimate of
the treatment effect was zero (no effect) in one country,
and negative (control better than treatment) in another.
Marschner [17] argues that such findings are often over-
interpreted, and proposes ways to assess the expected
variability in country-specific treatment effects at the
design stage. We showed that a post-hoc calculation of
the probability of a reversal of the treatment effect
(under some simplifying assumptions) can be useful to
address concerns that there is variability in treatment
effect between countries, over and above chance alone.
Such analyses may be especially relevant when potential
predictive factors are suspected to vary by region, per-
haps as a result of genetic differences related to
ethnicity.
When evaluating therapies for cancer, many factors
can influence the ability to detect a statistically signifi-
cant survival benefit. In the case of AML, a relatively
uncommon disease, enrollment of patients in large
enough numbers to adequately power a study for OS is
a major challenge. Second, long follow-up durations are
required, during which practice patterns change and
impact OS in ways extraneous to the treatment effect.
Third, most AML patients are older and have a higher
probability of death than younger patients (5-year survi-
val rates are 4% and 31% in persons ≥65 and <65 years
of age, respectively) [20] and such deaths in older
patients unrelated to leukemia have the potential to
confound interpretation of OS data [10]. Fourth, with
particular relevance to the study of remission mainte-
nance therapies in AML, patients may receive salvage
therapies post-relapse. Post-relapse salvage therapies are
far from standardized and have widely different mortal-
ity risks; hence, any observed differences in OS might
result from such therapies rather than from the rando-
mized intervention. For these reasons, LFS may be more
appropriate than OS to assess the benefit of strategies to
prevent AML relapse.
In the present trial, with the available follow-up data
at the time of the analysis, 236 patients had experienced
an event contributing to the LFS endpoint (110 in the
treatment group and 126 in the control group) and 196
patients had died (94 in the treatment group and 102 in
the control group). Hence, the power of the LFS analysis
was higher than that of the OS analysis and it was
expected, for this reason only, that a higher level of sig-
nificance would be reached for LFS than for OS. With
this in mind, it seemed useful to assess the correlation
between the effects of treatment on LFS and OS to bet-
ter understand whether treatment with HDC/IL-2 was
likely to have a real effect on OS, regardless of its (lack
of) statistical significance. We have explored this issue
using countries as the unit of analysis, extending meth-
ods that were initially proposed for meta-analyses of
several trials [18].
Conclusions
Our analyses confirm the consistency and robustness of
the HDC/IL-2 effect as compared with no treatment.
LFS may be an acceptable surrogate for OS in future
AML trials. Similar analyses may aid interpretation of
data from multicenter trials, especially in populations
with rare diseases, when the size of randomized clinical
trials is limited.
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